Author: Erasca, Inc.

Posted Date:

May 6, 2026

Erasca to Present at the Bank of America Securities Health Care Conference

Erasca, Inc.

May 6, 2026
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca, Inc.

April 27, 2026
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

Erasca, Inc.

April 27, 2026
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Erasca, Inc.

March 12, 2026
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

Erasca, Inc.

March 10, 2026
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Erasca, Inc.

March 5, 2026
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Erasca, Inc.

February 24, 2026
Erasca to Present at Upcoming Conferences in February

Erasca, Inc.

February 7, 2026
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Erasca, Inc.

January 28, 2026
Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca, Inc.

January 27, 2026